Physician profile
Janet Amaro
NPI 1568416477
$3,587.75
in general payments reported to CMS, 2019-2025
19 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $440 · 2021: $249 · 2022: $14.87 · 2023: $295 · 2024: $566 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $486.22 | 2019-2025 | Rexulti |
| Alkermes, INC. | $465.55 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $459.80 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $411.22 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $404.13 | 2019-2025 | Rexulti |
| Allergan, INC. | $246.81 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $246.39 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $216.74 | 2019-2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $201.29 | 2020-2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.22 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $78.38 | 2019-2020 | |
| Axsome Therapeutics, INC. | $68.27 | 2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $54.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.90 | 2025 | Trintellix |
| Acadia Pharmaceuticals INC | $32.61 | 2022-2023 | Nuplazid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.99 | 2020 | |
| Indivior INC. | $16.92 | 2024 | Perseris |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Amaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.